Materias dentro de su búsqueda.
Mostrando 2,181 - 2,200 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.30s Limitar resultados
  1. 2181
    “…Trastuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). HER2 is amplified or overexpressed in about 15% of breast cancers and is associated with aggressive disease. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer
  2. 2182
    “…Interestingly, these newly identified HER2 epitopes seem to be crucial for an effective immune response against HER2-overexpressing breast cancers and might help discriminating between metastatic breast cancer and early breast cancer patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Identification of Relevant Conformational Epitopes on the HER2 Oncoprotein by Using Large Fragment Phage Display (LFPD)
  3. 2183
    “…Majority of the patients (80%) had stage I disease at diagnosis. Information on HER2 status was available in 113 cases (85%). Of these, 31 cases (27.4%) were HER2+, higher than 18.8% reported in western population. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 Amplification and Clinicopathological Characteristics in a Large Asian Cohort of Rare Mucinous Ovarian Cancer
  4. 2184
    “…In the process of investigating the utility of a microfluidic platform for detecting HER2 gene amplification in these cells, we observed novel results on discordance of HER2 status. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer
  5. 2185
    “…Manual HER2 fluorescent in situ hybridisation (FISH) is the most readily used method to detect HER2 gene amplification which defines positive HER2 status in addition to HER2 protein overexpression. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparison of automated and manual FISH for evaluation of HER2 gene status on breast carcinoma core biopsies
  6. 2186
    por Shan, Ling, Ying, Jianming, Lu, Ning
    Publicado 2013
    “…In this study, the frequency of HER2 expression and the relationship between HER2 expression and clinicopathological features were examined in a large cohort of Chinese GC and GEJ cancer patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
  7. 2187
    “…A total of 102 patients with HER2-positive breast cancer were enrolled in part 2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
  8. 2188
    por Acharyya, Swarnali
    Publicado 2013
    “…HER2 amplification and overexpression is observed in approximately 20% of breast cancers and is strongly associated with poor prognosis and therapeutic responsiveness to HER2 targeted agents. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression
  9. 2189
    “…Treating salivary gland tumors, which have Her2/neu over-expression, with trastuzumab was reported in a few case reports. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
  10. 2190
    “…The aim of this study was to determine the frequency of EGFR, KRAS, BRAF, and HER-2 mutations in brain metastases from non-small cell lung carcinomas (BM-NSCLC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
  11. 2191
    “…The structural basis for Her2 heterodimerization, however, remains poorly understood. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family
  12. 2192
    “…METHODS: Patients with HER-negative operable stage II–III BC ≥2 cm were enrolled. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
  13. 2193
    “…METHODS: We established isogenic stable cell lines representing TNBC and Human Epidermal Growth Factor Receptor 2 positive (HER2+) breast cancers by introducing HER2 in TNBC cell lines MDA-MB-231 and MDA-MB-468. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Genomic Insights into Triple-Negative and HER2-Positive Breast Cancers Using Isogenic Model Systems
  14. 2194
    “…Data characterizing demographics, treatment patterns, and clinical outcomes in black patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) are limited. registHER is a large, observational cohort study of patients (n = 1,001) with HER2-positive MBC diagnosed ≤6 months of enrollment and followed until death, disenrollment, or June 2009 (median follow-up of 27 months). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
  15. 2195
    “…Human epidermal growth factor receptor 2 (HER2) has been evaluated in breast cancer patients to identify those most likely to benefit from herceptin-targeted therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas
  16. 2196
    “…However, there is currently no in vivo model for the study of HER2(+) BCSCs. In this study, we characterized a mouse breast cancer model for HER2(+) BCSCs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Characterization of a Novel Transgenic Mouse Tumor Model for Targeting HER2+ Cancer Stem Cells
  17. 2197
    por Olson, Erin, Mullins, D’Anna
    Publicado 2013
    “…The area of HER2-positive breast cancer is a rapidly changing field. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    When Standard Therapy Fails in Breast Cancer: Current and Future Options for HER2-Positive Disease
  18. 2198
    “…The over-expression of HER-2/neu has been observed in 6 patients (10%) and this over-expression was greater in the intestinal type of gastric adenocarcinoma than the diffuse type (12% vs. 6%); however, no statistically significant correlation between HER-2/neu expression and subtype, degree of differentiation, tumor type and age was observed. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma
  19. 2199
    “…A high number of these patients have Her2 overexpression. The goal of this study is to assess the Her2 status in muscle invasive urothelial bladder carcinoma, to evaluation heterogeneity and discordance with metastases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Status of Her2 over expression in muscle invasive urothelial bladder carcinoma: Report of 21 cases
  20. 2200
    “…The epidermal growth factor receptors are EGFR, HER2, HER3 and HER4. Of the four epidermal growth factor receptors, EGFR and HER2 are well-known oncogenes involved in gastric cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expression of the EGF Family in Gastric Cancer: Downregulation of HER4 and Its Activating Ligand NRG4
Herramientas de búsqueda: RSS